Year-end Sale % OFF 
Abstract
Objective:To compare the outcomes of antagonist stimulation protocols and to compare the cost effectiveness.Materials and Methods:Between 2011 and December 2017, a total of 354 women who underwent intracytoplasmic sperm injection and controlled ovarian stimulation with antagonist protocols were enrolled in the study. The antagonist implementation on the day of human chorionic gonadotropin (hCG) was continued for 194 of women, whereas the antagonist was stopped 36 hours before in 160 women. The stimulation outcomes of patients and cost-effectiveness of the regimens were compared.Results:There was a significant difference between the groups in terms of number of cryopreserved embryos, mature/immature oocyte ratio, and embryo transfer cancellations (p<0.05). The median value for the mature/immature oocyte ratio was 1.1 (0.2-7.5) and 1 (0.5-15) (p=0.001), and the ET cancellation was 5.3% vs. 1% for group 1 and 2, respectively (p=0.037). There was no difference between the groups in terms of pregnancy rates (p=0.197).Conclusion:No difference was found in the clinical pregnancy rates between the two groups. For this reason, the cessation of antagonist implementation on the day of hCG seems more advantageous in terms of cost-effectiveness and fewer injections.
Highlights
Gonadotrophin-releasing hormone (GnRH) antagonists have been used since 1999 in to prevent the luteinizing hormone (LH) peak in controlled ovarian stimulation[1,2]
GnRH antagonists suppress the release of follicle-stimulating hormone (FSH), and especially that of LH by competitively blocking the GnRH receptors in the anterior pituitary
GnRH antagonists suppress the pulsatile secretion of LH for 456 minutes[11] and we aimed to systematically collate evidence on the clinical efficacy of GnRH agonist triggering in patients undergoing assisted reproduction in GnRH antagonist protocols
Summary
Gonadotrophin-releasing hormone (GnRH) antagonists have been used since 1999 in to prevent the luteinizing hormone (LH) peak in controlled ovarian stimulation[1,2]. PRECIS: Cessation of antagonist implementation on the day of hCG seems more advantageous in terms of cost-effectiveness without an effect on clinical pregnancy rate.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
